SavedAdd your journal

Journals / Turkish Journal of Hematology / 2011 / Cilt: 28 - Sayı: 3

İmatinib alan bir kronik miyeloid lösemi olgusunda gelişen non-Hodgkin lenfoma

Non-Hodgkin's lymphoma in a chronic myelocytic leukemia patient treated with imatinib

SEMRA PAYDAŞ
Berna DUMAN BOZKURT
Melek ERGİN
Pages
232–234
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Herein we present a CML case that developed non-Hodgkin’s lymphoma (NHL) while receiving imatinib treatment.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Imatinib is an important example of tyrosine kinase inhibitors (TKIs) used in clinical practice.
📊
Key Findings & Data:Imatinib blocks the ATP binding site of the Bcr-Abl fusion protein and selectively inhibits Bcr-Abl tyrosine kinase (TK) activity.
💡
Conclusion & Impact:Herein we present a CML case that developed non-Hodgkin’s lymphoma (NHL) while receiving imatinib treatment.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Imatinib is an important example of tyrosine kinase inhibitors (TKIs) used in clinical practice. Imatinib blocks the ATP binding site of the Bcr-Abl fusion protein and selectively inhibits Bcr-Abl tyrosine kinase (TK) activity. Treatment of chronic myelocytic leukemia (CML) with imatinib is encouraging and it has an acceptable toxicity profile, and as such has changed the management of CML during the last decade. As with all drugs used in clinical practice, side effects of imatinib have been reported in studies with extended follow-up periods. In addition, some neoplastic disorders have been reported to occur during imatinib therapy. Herein we present a CML case that developed non-Hodgkin’s lymphoma (NHL) while receiving imatinib treatment.

Özet

İmatinib klinikte kullanılan tirozin kinaz (TK) inhibitörlerinin önemli bir örneğidir. Bcr Abl füzyon proteininin ATP bağlayan bölgesini bloke eder ve selektif olarak TK aktivitesini bloke eder. Kronik miyeloid lösemide (KML) imatinib'e yanıt heyecan vericidir ve kabul edilebilir toksisite profiline sahiptir. Bu özellikleri ile son on yılda KML yönetimini değiştirmiştir. Klinikte kullanılan her ilaçta olduğu gibi bazı yan etkiler uzun süreli takipte rapor edilmektedir. Diğer yan etkilerine ek olarak, imatinib tedavisi sırasında bazı neoplastik bozukluklar yayımlanmıştır. Burada KML nedeniyle imatinib almakta iken non-Hodgkin lenfoma (NHL) gelişen bir olgu sunulmuştur.

🔖

Cite This Article

PAYDAŞ, S., BOZKURT, B. D., ERGİN, M. (2011). İmatinib alan bir kronik miyeloid lösemi olgusunda gelişen non-Hodgkin lenfoma. Turkish Journal of Hematology, Cilt: 28 - Sayı: 3, 232–234. https://ajindex.com/articles/413149

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Miyazaki K, Kon S, Watanabe T, Togano T, Ohsaka M, Suzuki Y, Danbara M, Horie R, Kanda Y, Maruta A, Higashihara M. Early blastic transformation within a year of imatinib treatment in 2 cases of chronic myeloid leu- kemia. Rinsho Ketsueki. 2007;48:297-304
  2. Andersen MK, Pedersen-Bjergaard J, Kjedsen L, Dufva IH, Brondum K. Clonal Ph-negative hematopoiesis in CML after therapy with imatinib mesylate is frequently characterized by trisomy 8. Leukemia 2002;16:1390-5
  3. Chee YL, Vickers MA, Stevenson D, H olyoake TL, Culligan DJ. Fatal myelodysplastic syndrome developing during therapy with imatinib mesylate and character- ised by the emergence of complex Philadelphia nega- tive clones. Leukemia 2003;17:634-5
  4. Kovitz C, Kantarjian H, Garcia-Manero G, Abruzzo LV, Cortes J. Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myelocytic leukemia. Blood 2006;108:2811-3
  5. Ross DM, Jackson SR, Browett PJ. Phialdelphia-negative secondary acute myeloid leukaemia during imatinib treatment for chronic phase myelocytic leukaemia. Leuk Lymphoma 2007;48:1231-3
  6. Baskaynak G, Kreuzer KA, Schwarz M, Zuber J, Audring H, Riess H, Dörken B, Coutre P Squamous cutaneous epithelial cell carcinoma in two CML patients with progressive disease under imatinib treatment. Eur J Haematol. 2003;70:231-4
  7. Garipidou V, Vakalopoulou S, Tzimalos K. Development of multiple myeloma in a patient with chronic myelocytic leukemia after treatment with imatinib mesylate. Oncologist 2005;10:457-8
  8. Bekkenk MW, Vermeer MH, Meijer C, Jansen P, Middeldorp J, Stevens S, ReinWillemze. EBV-positive cutaneous B-cell lymphoproliferative disease after ima- tinib mesylate. Blood 2003;102:4243
  9. Leguay T, Foucaud C, Parrens M, Fitoussi O, Bouabdallah K, Belaud-Rotureau MA, Tabrizi R, Marit G, Pigneux A, Milpie N. EBV-positive lymphoproliferative disease with medullary, splenic and hepatic infiltration after imatinib mesylate therapy for chronic myeloid leukemia. Leukemia 2007;1-3
  10. Paydas S, Zorludemir S, Ergin M. Granulocytic sarcoma: 32 cases and review of the literature. Leuk Lymphoma 2006;47:2527-41
  11. Seggewiss R, Lore K, Greiner E, Magnusson MK, Price DA, Douek DC, Dunbar CE, Wiestner A. Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner. Blood 2005;105:2473-9
  12. Fabarius A, Giehl M, Frank O, Hochhaus A, Hehlmann R, Seifarth W. Induction of centrosome aberrations by ima- tinib i